2 sourcesTracking since 8h ago
<a href="https://www.fiercebiotech.com/biotech/its-cancer-and-inflammation-expansion-critical-mass-gileads-oday-eyes-companys-next-chapter" hreflang="en">CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’</a>
Chronological coverage
First seen8h ago<a href="https://www.fiercebiotech.com/biotech/its-cancer-and-inflammation-expansion-critical-mass-gileads-oday-eyes-companys-next-chapter" hreflang="en">CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’</a>
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammation, CEO Daniel O’Day told Fierce.
Fierce Biotech•Darren Incorvaia
- Latest7h ago
<a href="https://www.fiercepharma.com/biotech/its-cancer-and-inflammation-expansion-critical-mass-gileads-oday-eyes-companys-next-chapter" hreflang="en">CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’</a>
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammation, CEO Daniel O’Day told Fierce.
Fierce Pharma•Darren Incorvaia